Ablynx will discover and develop osteoarthritis drugs with Merck Serono, marking the companies' third alliance that utilizes the former's nanobody platform. They previously agreed to work on therapeutic targets in
oncology and immunology as well as inflammation. All three deals entitle Ablynx to upfront and milestone fees.

Related Summaries